CAJ | 학술논문

目的：观察肝动脉栓塞化疗联合细胞因子诱导的杀伤细胞（CIK）疗法治疗原发性肝癌的临床疗效。方法对2008年3月至2009年5月接受肝动脉栓塞化疗联合体外培养CIK细胞14d后分次回输疗法的23例原发性肝癌患者（治疗组）与单纯肝动脉栓塞化疗21例患者（对照组）比较，观察患者治疗前后瘤体大小、免疫组化、临床症状、生活质量、卡氏评分、生存期等的变化。结果治疗组与对照组治疗前后CD3+、CD4+、CD4+/CD8+、NK有统计学意见（P<0.05），治疗后患者临床症状较治疗前有明显改善，差异有统计学意义（P<0.05），卡氏评分提高率为82.6%，治疗组与对照组中位生存期分别为22个月、11个月，治疗组生存期明显长于对照组（P<0.05）。结论肝动脉栓塞化疗联合CIK细胞疗法较单纯肝动脉栓塞化疗有可能提高原发性肝癌患者的远期生存率，延缓肝癌复发。
목적：관찰간동맥전새화료연합세포인자유도적살상세포（CIK）요법치료원발성간암적림상료효。방법대2008년3월지2009년5월접수간동맥전새화료연합체외배양CIK세포14d후분차회수요법적23례원발성간암환자（치료조）여단순간동맥전새화료21례환자（대조조）비교，관찰환자치료전후류체대소、면역조화、림상증상、생활질량、잡씨평분、생존기등적변화。결과치료조여대조조치료전후CD3+、CD4+、CD4+/CD8+、NK유통계학의견（P<0.05），치료후환자림상증상교치료전유명현개선，차이유통계학의의（P<0.05），잡씨평분제고솔위82.6%，치료조여대조조중위생존기분별위22개월、11개월，치료조생존기명현장우대조조（P<0.05）。결론간동맥전새화료연합CIK세포요법교단순간동맥전새화료유가능제고원발성간암환자적원기생존솔，연완간암복발。
Objective Observe the hepatic artery embolization chemotherapy combined cytokine-induced killer cells (CIK) the clinical curative effect of the treatment of primary liver cancer. Methods In March 2008 to may accept hepatic artery embolization combined chemotherapy in vitro culture CIK cells after 14 d time back to lose points of the 23 cases of primary liver cancer therapy patients (treatment group) and simple hepatic artery embolization chemotherapy 21 patients (control group) comparison, Changes in tumor size before and after the observation of patients, immunohistochemistry, clinical symptoms, quality of life, Karnofsky performance status, survival time, etc. Results treatment group and control group before and after treatment levels of CD3+and CD4+, CD4+/CD8+and NK statistical views (P<0.05), after treatment, the clinical symptoms than before treatment were obviously improved, the difference was statistically signiifcant (P<0.05), Karnofsky performance status increase rate was 82.6%, the treatment group and control group median survival respectively for 22 months, 11 months, the treatment group surial obvious longer than in control group (P<0.05). Conclusion Hepatic artery embolization combined chemotherapy CIK cell therapy is purer hepatic artery embolization chemotherapy may improve the primary liver cancer patients of the long-term survival, delay liver cancer recurrence.